Healthcare / BiotechnologyTaipei Exchange
$29.90
-0.40 (-1.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-67.6M · quality 62.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-32.5%
↓Gross Margin
87.7%
↑Debt/Equity
0.33
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.5%
FCF CAGR
—
FCF margin
-3679.1%
FCF / Net income
0.97x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.6M · net income $-99.8M · FCF $-96.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.6M | $2.6M | $12.3M | $1.2M | $2.2M |
| Net Income | $-99.8M | $-99.8M | $-87.6M | $-73.3M | $-70.9M |
| EBITDA | $-90.0M | $-90.0M | $-76.6M | $-62.3M | $-53.8M |
| EPS | — | — | -2.47 | -2.16 | -2.03 |
| Gross Margin | 87.7% | 87.7% | 96.4% | 89.7% | 89.5% |
| Operating Margin | -3832.1% | -3832.1% | -697.4% | -6007.0% | -3252.7% |
| Net Margin | -3800.8% | -3800.8% | -712.0% | -6066.6% | -3258.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.33 | 0.33 | 0.26 | 0.81 | 0.87 |
| Cash Flow | |||||
| Free Cash Flow | $-96.7M | $-96.7M | $-67.6M | $-65.7M | $-207.3M |
| Returns | |||||
| ROE | -32.5% | -32.5% | -21.5% | -52.4% | -50.5% |
| Valuation | |||||
| P/B | 4.81 | 4.81 | 2.72 | 9.31 | 9.16 |
| Growth & Yield | |||||
| Revenue Growth | -78.6% | -78.6% | 918.0% | -44.5% | — |
| EPS Growth | — | — | -14.4% | -6.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.47 → n/d
Residual
+7.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.